CML
MCID: LKM063
MIFTS: 74

Leukemia, Chronic Myeloid (CML)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Chronic Myeloid

MalaCards integrated aliases for Leukemia, Chronic Myeloid:

Name: Leukemia, Chronic Myeloid 57 53 74 13 38
Chronic Myelogenous Leukemia 12 75 53 25 59 74 29 6 15 17
Chronic Myeloid Leukemia 12 53 25 59 37 43 15
Cml 57 12 53 25 59 74
Chronic Granulocytic Leukemia 12 53 25 59
Leukemia, Philadelphia Chromosome-Positive, Resistant to Imatinib 57 6
Myeloid Leukemia, Chronic 12 72
Leukemia, Chronic Myeloid, Philadelphia Chromosome Positive, Somatic 57
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 72
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 74
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive 44
Leukemia, Chronic Myeloid, Atypical 74
Cml - Chronic Myelogenous Leukemia 12
Leukemia, Chronic Myelogenous 57
Chronic Myelocytic Leukemia 25
Leukemia, Myeloid, Chronic 40
Myeloid Leukemia Chronic 55
Acml 74
Cgl 25

Characteristics:

Orphanet epidemiological data:

59
chronic myeloid leukemia
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (United States); Age of onset: Adult;

OMIM:

57
Inheritance:
somatic mutation


HPO:

32
leukemia, chronic myeloid:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:8552
OMIM 57 608232
KEGG 37 H00004
ICD9CM 35 205.1
MeSH 44 D015464
NCIt 50 C3174
SNOMED-CT 68 63364005 92818009
ICD10 33 C92.2
ICD10 via Orphanet 34 C92.1
UMLS via Orphanet 73 C0023473
Orphanet 59 ORPHA521
UMLS 72 C0023473 C1292772

Summaries for Leukemia, Chronic Myeloid

Genetics Home Reference : 25 Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In chronic myeloid leukemia, the bone marrow produces too many white blood cells. Initially, these cells function relatively normally. However, as the condition progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. The overgrowth of myeloblasts impairs development of other blood cells, leading to a shortage of red blood cells (anemia) and platelets. Chronic myeloid leukemia usually begins after age 60. Common features include excessive tiredness (fatigue), fever, and weight loss. Many affected individuals develop an enlarged spleen (splenomegaly), which can cause a feeling of fullness in the abdomen and a loss of appetite. About half of people with chronic myeloid leukemia do not initially have any signs and symptoms and are diagnosed when a blood test is performed for another reason. The condition consists of three phases: the chronic phase, the accelerated phase, and the blast phase (or blast crisis). In the chronic phase, the number of mature white blood cells is elevated, and myeloblasts account for less than 10 percent of blood cells. Signs and symptoms of the condition during this phase are typically mild or absent and worsen slowly. The chronic phase can last from months to years. In the accelerated phase, the number of myeloblasts is slightly higher, making up 10 to 29 percent of blood cells. The signs and symptoms continue to worsen. The accelerated phase usually lasts 4 to 6 months, although it is skipped in some affected individuals. In blast crisis, 30 percent or more of blood or bone marrow cells are myeloblasts. Signs and symptoms are most severe in this phase, including a massively enlarged spleen, bone pain, and weight loss. Serious infections and uncontrolled bleeding can be life-threatening.

MalaCards based summary : Leukemia, Chronic Myeloid, also known as chronic myelogenous leukemia, is related to philadelphia-negative chronic myeloid leukemia and atypical chronic myeloid leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Chronic Myeloid is ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase), and among its related pathways/superpathways are Chronic myeloid leukemia and Endometrial cancer. The drugs Thiotepa and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are myeloproliferative disorder and splenomegaly

Disease Ontology : 12 A myeloid leukemia that is characterized by over production of white blood cells.

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 521DefinitionChronic myeloid leukaemia (CML) is the most common myeloproliferative disorder accounting for 15-20% of all leukaemia cases.EpidemiologyIts annual incidence has been estimated at between 1 and 1.5 cases per 100,000 and its prevalence at around 1 in 17,000.Clinical descriptionThe disease is typically triphasic with a chronic phase (CML-CP), accelerated phase (CML-AP) and blast phase (CML-BP). The majority of patients are diagnosed in the chronic phase and may be either asymptomatic (diagnosed through a routine white blood cell count) or present with fatigue, anaemia, weight loss, night sweats or splenomegaly.EtiologyCML is characterised by the presence of the Philadelphia chromosome, an abnormality resulting from a balanced translocation between chromosomes 9 and 22 (t(9;22)(q34;q11.2)). This translocation generates a BCR/ABL gene fusion encoding a constitutively active tyrosine kinase. CML does not appear to be an inherited disease and the factors leading to predisposition for the disorder remain largely unknown.Management and treatmentAlthough an allogeneic bone marrow transplant is viewed as the only curative treatment option, the prognosis for patients improved dramatically with the targeted development of imatinib mesylate. Imatinib mesylate is a competitive inhibitor of BCR/ABL tyrosine kinase activity and has held EU marketing authorisation as an Orphan drug for the treatment of CML since 2001.Visit the Orphanet disease page for more resources.

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic myeloid leukemia (CML), there are too many granulocytes, a type of white blood cell. Most people with CML have a gene mutation (change) called the Philadelphia chromosome. Sometimes CML does not cause any symptoms. If you have symptoms, they may include: Fatigue Weight loss Night sweats Fever Pain or a feeling of fullness below the ribs on the left side Tests that examine the blood and bone marrow diagnose CML. Treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

KEGG : 37
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22. The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.

UniProtKB/Swiss-Prot : 74 Leukemia, chronic myeloid: A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts. Leukemia, chronic myeloid, atypical: A myeloproliferative disorder that shares clinical and laboratory features with chronic myeloid leukemia but lacks the pathognomonic Philadelphia chromosome and the corresponding BCR/ABL1 fusion transcript. Features include myeloid predominance in the bone marrow, myeloid proliferation and low leukocyte alkaline phosphatase value, splenomegaly, hepatomegaly, elevated white blood cell count. Enlarged spleen may also be associated with a hypermetabolic state, fever, weight loss, and chronic fatigue. The enlarged liver may contribute to the patient's weight loss.

Wikipedia : 75 Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white... more...

More information from OMIM: 608232

Related Diseases for Leukemia, Chronic Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Chronic Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 827, show less)
# Related Disease Score Top Affiliating Genes
1 philadelphia-negative chronic myeloid leukemia 35.5 BCR ABL1
2 atypical chronic myeloid leukemia 34.8 SETBP1 RUNX1 JAK2 CSF3R ABL1
3 leukemia 34.3 RUNX1 NRAS KIT JAK2 HOTAIR CSF3R
4 polycythemia vera 34.2 KIT JAK2 H19 ABL1
5 juvenile myelomonocytic leukemia 34.1 SETBP1 RUNX1 NRAS JAK2
6 myeloid leukemia 33.1 RUNX1 NRAS KIT JAK2 CSF3R BCR
7 myelofibrosis 32.6 MIR223 MEG3 KIT JAK2
8 essential thrombocythemia 32.4 MIR223 JAK2 BCR ABL1
9 chronic leukemia 32.4 SETBP1 JAK2 CSF3R BCR
10 myeloma, multiple 32.3 UCA1 NRAS MEG3 KIT JAK2 HOTAIR
11 hematologic cancer 32.1 RUNX1 KIT JAK2 CSF3R BCR ABL1
12 myeloproliferative neoplasm 31.8 KIT JAK2 H19 BCR ABL1
13 leukemia, acute lymphoblastic 31.8 RUNX1 MIR223 MIR203A BCR ABL1
14 leukemia, acute lymphoblastic 3 31.8 RUNX1 BCR ABL1
15 leukemia, acute myeloid 31.8 UCA1 SETBP1 RUNX1 NRAS MIR223 MEG3
16 diffuse large b-cell lymphoma 31.7 MIR10A HULC HOTAIR
17 thyroid cancer, nonmedullary, 1 31.7 MEG3 HULC HOTAIR H19
18 nasopharyngeal carcinoma 31.6 NRAS MEG3 HULC HOTAIR H19
19 gastric cancer 31.6 UCA1 MIR223 MIR20A MIR203A MEG3 HULC
20 kidney cancer 31.6 MIR20A MIR17 MEG3 HOTAIR H19
21 colorectal cancer 31.5 UCA1 NRAS MIR223 MIR20A MIR203A MIR10A
22 bladder cancer 31.5 UCA1 MIR223 MIR203A MIR10A MEG3 HULC
23 pancreatic cancer 31.5 UCA1 MIR223 MIR20A MIR203A MIR10A MEG3
24 chronic myelomonocytic leukemia 31.4 SETBP1 RUNX1 KIT JAK2 CSF3R
25 renal cell carcinoma, nonpapillary 31.3 UCA1 KIT HOTAIR H19
26 myelodysplastic syndrome 31.3 SETBP1 RUNX1 NRAS MIR10A MEG3 KIT
27 osteogenic sarcoma 31.3 UCA1 MEG3 HULC HOTAIR H19
28 cervical cancer 31.3 UCA1 MEG3 HULC HOTAIR H19
29 esophageal cancer 31.3 UCA1 MIR223 MIR203A MEG3 HULC HOTAIR
30 medulloblastoma 31.2 NRAS MIR20A MIR17 HOTAIR H19
31 psoriasis 31.2 MIR20A MIR203A MIR10A
32 hepatocellular carcinoma 31.2 UCA1 NRAS MIR223 MIR20A MIR203A MEG3
33 acute promyelocytic leukemia 31.2 RUNX1 NRAS MIR223 CSF3R
34 melanoma 31.2 UCA1 NRAS MEG3 HOTAIR H19
35 ovarian cancer 31.1 UCA1 MIR223 MEG3 HOTAIR H19 ABL1
36 gastric adenocarcinoma 31.0 NRAS KIT HOTAIR H19
37 aggressive systemic mastocytosis 31.0 KIT H19
38 acute leukemia 30.9 RUNX1 KIT JAK2
39 lung cancer susceptibility 3 30.7 NRAS MEG3 HOTAIR H19
40 congenital generalized lipodystrophy 11.7
41 pdgfrb-associated chronic eosinophilic leukemia 11.6
42 myelodysplastic/myeloproliferative neoplasm 11.4
43 myelocytic leukemia-like syndrome, familial, chronic 11.4
44 lipodystrophy, congenital generalized, type 2 11.2
45 lipodystrophy, congenital generalized, type 1 11.2
46 ovarian epithelial cancer 11.1 MEG3 HULC HOTAIR H19
47 bone marrow cancer 11.1 RUNX1 KIT JAK2 CSF3R BCR ABL1
48 neutrophilia, hereditary 11.1 MIR223 JAK2 CSF3R
49 core binding factor acute myeloid leukemia 11.1 RUNX1 NRAS KIT JAK2
50 functionless pituitary adenoma 11.1 MEG3 HOTAIR
51 pituitary adenoma 11.1 MIR223 MEG3 HOTAIR H19
52 gastric cardia adenocarcinoma 11.1 MEG3 HOTAIR H19
53 pancreatic ductal adenocarcinoma 11.1 UCA1 MIR223 MIR203A HOTAIR H19
54 oral squamous cell carcinoma 11.1 UCA1 MIR223 MIR203A MIR10A MEG3 HOTAIR
55 8p11 myeloproliferative syndrome 11.1 RUNX1 KIT BCR
56 glioma 11.0 UCA1 MIR20A MIR17 MEG3 HULC HOTAIR
57 adamantinoma of long bones 11.0 UCA1 MEG3 HULC HOTAIR H19
58 chromosome 22q11.2 deletion syndrome, distal 11.0 CRKL BCR
59 gallbladder cancer 11.0 UCA1 MEG3 HOTAIR H19
60 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.0 RUNX1 KIT
61 bladder urothelial carcinoma 11.0 NRAS MEG3 KIT HOTAIR
62 esophagus squamous cell carcinoma 11.0 MEG3 HOTAIR
63 prostate cancer 11.0 UCA1 MIR223 MIR20A MIR203A MIR10A MEG3
64 gastrointestinal system cancer 11.0 KIT HOTAIR H19
65 endometriosis 10.9 MIR223 MIR20A H19
66 ovarian melanoma 10.9 NRAS KIT
67 conventional fibrosarcoma 10.9 NRAS KIT
68 graft-versus-host disease 10.9
69 endometrial cancer 10.9 UCA1 MEG3 KIT HOTAIR H19
70 lung cancer 10.9 UCA1 NRAS MIR20A MIR203A MEG3 KIT
71 acral lentiginous melanoma 10.9 NRAS KIT
72 malignant spindle cell melanoma 10.8 NRAS KIT
73 acute graft versus host disease 10.8
74 exanthem 10.7
75 chronic graft versus host disease 10.5
76 severe combined immunodeficiency 10.5
77 myeloid sarcoma 10.5
78 polycythemia 10.5
79 sarcoma 10.4
80 spindle cell sarcoma 10.4
81 gastrointestinal stromal tumor 10.4
82 lymphoma 10.4
83 b-cell lymphoma 10.4
84 pulmonary hypertension 10.4
85 mucositis 10.4
86 chronic neutrophilic leukemia 10.4
87 48,xyyy 10.4
88 withdrawal disorder 10.3
89 bilirubin metabolic disorder 10.3
90 lymphoma, hodgkin, classic 10.3
91 neuropathy 10.3
92 cytokine deficiency 10.3
93 pik3ca-related overgrowth syndrome 10.3
94 dowling-degos disease 1 10.3
95 pericarditis 10.3
96 autoimmune disease 10.2
97 retinoblastoma 10.2
98 lymphoma, non-hodgkin, familial 10.2
99 aspergillosis 10.2
100 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
101 hypophosphatemia 10.2
102 nephrotic syndrome 10.2
103 purpura 10.2
104 familial retinoblastoma 10.2
105 lysosomal storage disease 10.2
106 neurofibromatosis, type iv, of riccardi 10.2
107 neutrophilic dermatosis, acute febrile 10.2
108 hypothyroidism 10.2
109 peripheral nervous system disease 10.2
110 megakaryocytic leukemia 10.2
111 homologous wasting disease 10.2
112 hypertriglyceridemia, familial 10.2
113 bronchiolitis obliterans 10.2
114 bronchiolitis 10.2
115 breast cancer 10.2
116 pulmonary hypertension, primary, 1 10.2
117 branchiootic syndrome 1 10.2
118 microvascular complications of diabetes 5 10.2
119 lung disease, immunodeficiency, and chromosome breakage syndrome 10.2
120 peripheral vascular disease 10.2
121 colitis 10.2
122 lymphoblastic lymphoma 10.2
123 hypopyon 10.2
124 allergic hypersensitivity disease 10.2
125 pulmonary alveolar proteinosis 10.2
126 uveitis 10.2
127 diarrhea 10.2
128 polyneuropathy 10.2
129 vascular disease 10.2
130 calcinosis 10.2
131 viral hepatitis 10.2
132 hepatitis b 10.2
133 iron metabolism disease 10.2
134 skin carcinoma 10.2
135 kidney disease 10.2
136 hemolytic anemia 10.2
137 alopecia 10.2
138 avascular necrosis 10.2
139 erythroleukemia, familial 10.1
140 fibrosis of extraocular muscles, congenital, 1 10.1
141 anemia, autoimmune hemolytic 10.1
142 myasthenia gravis 10.1
143 sickle cell anemia 10.1
144 immunodeficiency, common variable, 10 10.1
145 follicular lymphoma 10.1
146 respiratory failure 10.1
147 disseminated intravascular coagulation 10.1
148 hemopericardium 10.1
149 pericardial effusion 10.1
150 telangiectasis 10.1
151 pure red-cell aplasia 10.1
152 optic nerve disease 10.1
153 agammaglobulinemia 10.1
154 pustulosis of palm and sole 10.1
155 herpes zoster 10.1
156 vasculitis 10.1
157 granulocytopenia 10.1
158 complex chromosomal rearrangement 10.1
159 red cell aplasia 10.1
160 thyroid carcinoma 10.1
161 splenomegaly 10.1
162 neurofibromatosis, type i 10.1
163 langerhans cell histiocytosis 10.1
164 hypogonadotropic hypogonadism 10.1
165 embryoma 10.1
166 mucopolysaccharidosis-plus syndrome 10.1
167 spondyloarthropathy 1 10.1
168 hypercholesterolemia, familial, 1 10.1
169 li-fraumeni syndrome 10.1
170 retinal detachment 10.1
171 sarcoidosis 1 10.1
172 immune deficiency disease 10.1
173 li-fraumeni syndrome 2 10.1
174 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
175 peripheral artery disease 10.1
176 nasopharyngitis 10.1
177 hydrocephalus 10.1
178 cardiac tamponade 10.1
179 portal vein thrombosis 10.1
180 iron deficiency anemia 10.1
181 inflammatory spondylopathy 10.1
182 cystitis 10.1
183 retinal vein occlusion 10.1
184 autoimmune hepatitis 10.1
185 central retinal vein occlusion 10.1
186 dermatitis 10.1
187 hairy cell leukemia 10.1
188 adenocarcinoma 10.1
189 lipid metabolism disorder 10.1
190 skin disease 10.1
191 thyroid gland papillary carcinoma 10.1
192 systemic scleroderma 10.1
193 hyperglycemia 10.1
194 myopathy 10.1
195 infertility 10.1
196 lymphopenia 10.1
197 combined t cell and b cell immunodeficiency 10.1
198 connective tissue disease 10.1
199 spondylitis 10.1
200 compartment syndrome 10.1
201 sideroblastic anemia 10.1
202 hard palate cancer 10.1
203 intracranial hypertension 10.1
204 meningitis 10.1
205 stomatitis 10.1
206 miliary tuberculosis 10.1
207 toxoplasmosis 10.1
208 acute myeloblastic leukemia with maturation 10.1
209 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.1
210 acute non lymphoblastic leukemia 10.1
211 bone marrow necrosis 10.1
212 congenital hydrocephalus 10.1
213 polymyositis 10.1
214 thrombasthenia 10.1
215 hypoxia 10.1
216 syncope 10.1
217 acute liver failure 10.1
218 overgrowth syndrome 10.1
219 leukemia, chronic lymphocytic 10.1
220 lymphocytic leukemia 10.1
221 leukemia, b-cell, chronic 10.1
222 ulcerative colitis 10.1
223 pfeiffer syndrome 10.0
224 behcet syndrome 10.0
225 leukemia, acute monocytic 10.0
226 cryptogenic organizing pneumonia 10.0
227 bone disease 10.0
228 bacterial infectious disease 10.0
229 primary hyperparathyroidism 10.0
230 squamous cell carcinoma 10.0
231 giant cell tumor 10.0
232 chronic granulomatous disease 10.0
233 progressive multifocal leukoencephalopathy 10.0
234 acute myocardial infarction 10.0
235 acute erythroid leukemia 10.0
236 acute basophilic leukemia 10.0
237 arteries, anomalies of 10.0
238 hypercalcemia, infantile, 1 10.0
239 myositis 10.0
240 pelger-huet anomaly 10.0
241 polykaryocytosis inducer 10.0
242 porphyria cutanea tarda 10.0
243 scleroderma, familial progressive 10.0
244 fanconi anemia, complementation group d2 10.0
245 fanconi anemia, complementation group a 10.0
246 gaucher disease, type i 10.0
247 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
248 scott syndrome 10.0
249 thymoma, familial 10.0
250 yemenite deaf-blind hypopigmentation syndrome 10.0
251 microvascular complications of diabetes 1 10.0
252 body mass index quantitative trait locus 1 10.0
253 kala-azar 1 10.0
254 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
255 intraocular pressure quantitative trait locus 10.0
256 microvascular complications of diabetes 2 10.0
257 dengue virus 10.0
258 membranous nephropathy 10.0
259 helix syndrome 10.0
260 anaplastic large cell lymphoma 10.0
261 hemorrhagic cystitis 10.0
262 paroxysmal nocturnal hemoglobinuria 10.0
263 thrombosis 10.0
264 hepatic veno-occlusive disease 10.0
265 acquired von willebrand syndrome 10.0
266 sensorineural hearing loss 10.0
267 osteomyelitis 10.0
268 dermatomyositis 10.0
269 thalassemia 10.0
270 portal hypertension 10.0
271 pulmonary edema 10.0
272 infant gynecomastia 10.0
273 optic neuritis 10.0
274 vogt-koyanagi-harada disease 10.0
275 von willebrand's disease 10.0
276 hemolytic-uremic syndrome 10.0
277 gynecomastia 10.0
278 central nervous system leukemia 10.0
279 focal segmental glomerulosclerosis 10.0
280 porphyria 10.0
281 osteopetrosis 10.0
282 hyperparathyroidism 10.0
283 cholestasis 10.0
284 multiple cranial nerve palsy 10.0
285 gonadal dysgenesis 10.0
286 thrombocytopenia due to platelet alloimmunization 10.0
287 neovascular glaucoma 10.0
288 neuritis 10.0
289 impotence 10.0
290 hyperuricemia 10.0
291 hypogonadism 10.0
292 gaucher's disease 10.0
293 constipation 10.0
294 macrocytic anemia 10.0
295 splenic infarction 10.0
296 idiopathic interstitial pneumonia 10.0
297 acute pancreatitis 10.0
298 cryoglobulinemia 10.0
299 membranoproliferative glomerulonephritis 10.0
300 papillary carcinoma 10.0
301 ischemia 10.0
302 thymoma 10.0
303 systemic mastocytosis 10.0
304 turner syndrome 10.0
305 mastocytosis 10.0
306 kallmann syndrome 10.0
307 plasmacytoma 10.0
308 pyoderma 10.0
309 hypokalemia 10.0
310 pancreatitis 10.0
311 liver cirrhosis 10.0
312 adult acute lymphocytic leukemia 10.0
313 hemoglobinuria 10.0
314 acquired immunodeficiency syndrome 10.0
315 thyroiditis 10.0
316 hypogonadotropism 10.0
317 hyperthyroidism 10.0
318 cataract 10.0
319 mucormycosis 10.0
320 monocytic leukemia 10.0
321 pyoderma gangrenosum 10.0
322 herpes simplex 10.0
323 pyomyositis 10.0
324 leishmaniasis 10.0
325 macroglobulinemia 10.0
326 visceral leishmaniasis 10.0
327 exophthalmos 10.0
328 hemophilia 10.0
329 ltbp4-related cutis laxa 10.0
330 sickle cell disease 10.0
331 47, xxy 10.0
332 lichen planopilaris 10.0
333 lymphosarcoma 10.0
334 pseudo pelger-huet anomaly 10.0
335 syndrome of inappropriate antidiuretic hormone 10.0
336 raynaud phenomenon 10.0
337 headache 10.0
338 tremor 10.0
339 low-flow priapism 10.0
340 acute generalized exanthematous pustulosis 10.0
341 polyploidy 10.0
342 precursor t-cell acute lymphoblastic leukemia 10.0
343 thrombocytopenia 10.0
344 thrombocytosis 10.0
345 pituitary adenoma, prolactin-secreting 10.0
346 gallbladder disease 1 10.0
347 metabolic acidosis 10.0
348 ileitis 10.0
349 sialadenitis 10.0
350 pituitary apoplexy 10.0
351 locked-in syndrome 10.0
352 quadriplegia 10.0
353 acute closed-angle glaucoma 10.0
354 craniopharyngioma 10.0
355 loeffler endocarditis 10.0
356 rapidly progressive glomerulonephritis 10.0
357 ovarian cyst 10.0
358 reticulosarcoma 10.0
359 polyarteritis nodosa 10.0
360 microscopic polyangiitis 10.0
361 mycobacterium avium complex infections 10.0
362 trisomy 22 10.0
363 paresthesia 10.0
364 pneumococcal meningitis 10.0
365 rare surgical neurologic disease 10.0
366 adams-oliver syndrome 1 9.9
367 neurofibromatosis, type ii 9.9
368 arteriovenous malformations of the brain 9.9
369 fragile site 10q25 9.9
370 endosteal hyperostosis, autosomal dominant 9.9
371 lichen sclerosus et atrophicus 9.9
372 parkinson disease, late-onset 9.9
373 alkaline phosphatase, plasma level of, quantitative trait locus 1 9.9
374 williams-beuren syndrome 9.9
375 anemia, hypochromic microcytic, with iron overload 1 9.9
376 takayasu arteritis 9.9
377 enterocolitis 9.9
378 factor v deficiency 9.9
379 intracranial hypertension, idiopathic 9.9
380 familial mediterranean fever 9.9
381 oliver syndrome 9.9
382 stroke, ischemic 9.9
383 dermatitis, atopic 9.9
384 homocysteinemia 9.9
385 pulmonary disease, chronic obstructive 9.9
386 psoriatic arthritis 9.9
387 hepatitis c virus 9.9
388 diarrhea 6 9.9
389 human herpesvirus 8 9.9
390 t-cell lymphoma, subcutaneous panniculitis-like 9.9
391 chronic diarrhea due to guanylate cyclase 2c overactivity 9.9
392 hyperphosphatemia 9.9
393 hypochromic microcytic anemia 9.9
394 marginal zone b-cell lymphoma 9.9
395 peripheral t-cell lymphoma 9.9
396 villous adenoma 9.9
397 aphasia 9.9
398 adams-oliver syndrome 9.9
399 erythema elevatum diutinum 9.9
400 childhood acute lymphocytic leukemia 9.9
401 nodal marginal zone lymphoma 9.9
402 polycystic kidney disease 9.9
403 neuroretinitis 9.9
404 viral meningitis 9.9
405 microinvasive gastric cancer 9.9
406 short bowel syndrome 9.9
407 hemiplegia 9.9
408 brucellosis 9.9
409 acquired thrombocytopenia 9.9
410 anhidrosis 9.9
411 pertussis 9.9
412 spondyloarthropathy 9.9
413 microcytic anemia 9.9
414 constrictive pericarditis 9.9
415 horner's syndrome 9.9
416 nephrosclerosis 9.9
417 lyme disease 9.9
418 hemosiderosis 9.9
419 testicular lymphoma 9.9
420 nephrocalcinosis 9.9
421 acute cystitis 9.9
422 skin sarcoidosis 9.9
423 facial paralysis 9.9
424 alcoholic liver cirrhosis 9.9
425 renal tubular acidosis 9.9
426 adult-onset still's disease 9.9
427 alcohol use disorder 9.9
428 rheumatic disease 9.9
429 ichthyosis 9.9
430 hepatitis c 9.9
431 malignant fibroxanthoma 9.9
432 hepatitis 9.9
433 angiodysplasia 9.9
434 orchitis 9.9
435 benign mesothelioma 9.9
436 acute interstitial pneumonia 9.9
437 substance abuse 9.9
438 glioblastoma multiforme 9.9
439 proctitis 9.9
440 demyelinating disease 9.9
441 germinoma 9.9
442 breast adenocarcinoma 9.9
443 sagittal sinus thrombosis 9.9
444 plexopathy 9.9
445 granuloma annulare 9.9
446 lynch syndrome 9.9
447 histiocytoma 9.9
448 coronary stenosis 9.9
449 folliculitis 9.9
450 fibrous histiocytoma 9.9
451 seminoma 9.9
452 macular retinal edema 9.9
453 immune-complex glomerulonephritis 9.9
454 spinal stenosis 9.9
455 langerhans cell sarcoma 9.9
456 pineal region germinoma 9.9
457 active peptic ulcer disease 9.9
458 peptic ulcer disease 9.9
459 bacterial pneumonia 9.9
460 amyloidosis 9.9
461 diabetes mellitus 9.9
462 epididymo-orchitis 9.9
463 smoldering myeloma 9.9
464 fasciitis 9.9
465 hemorrhoid 9.9
466 irf6-related disorders 9.9
467 amyloidosis aa 9.9
468 chromosome 17p deletion 9.9
469 chromosome 20q deletion 9.9
470 chromosome 9 inversion 9.9
471 chromosome 9q duplication 9.9
472 diffuse cutaneous systemic sclerosis 9.9
473 dysfibrinogenemia 9.9
474 germ cells tumors 9.9
475 glioblastoma 9.9
476 growth hormone deficiency 9.9
477 ichthyosis, acquired 9.9
478 leukemia, t-cell, chronic 9.9
479 lichen sclerosus 9.9
480 mosaic trisomy 8 9.9
481 muscular dystrophy white matter spongiosis 9.9
482 mycobacterium kansasii 9.9
483 primary effusion lymphoma 9.9
484 pyogenic granuloma 9.9
485 testicular seminoma 9.9
486 tuberculous meningitis 9.9
487 undifferentiated pleomorphic sarcoma 9.9
488 multiple endocrine neoplasia 9.9
489 postherpetic neuralgia 9.9
490 refractory anemia with excess blasts in transformation 9.9
491 partial deletion of chromosome 7 9.9
492 rare hereditary hemochromatosis 9.9
493 ring chromosome 9.9
494 osteonecrosis of the jaw 9.9
495 bullous pyoderma gangrenosum 9.9
496 lymphedema 9.9
497 wilms tumor 1 9.9
498 wilms tumor 5 9.9
499 deficiency anemia 9.9
500 mantle cell lymphoma 9.9
501 osteonecrosis 9.9
502 neutropenia 9.9
503 pancytopenia 9.9
504 precursor b lymphoblastic lymphoma/leukemia 9.9
505 chronic monocytic leukemia 9.9
506 diabetes insipidus 9.9
507 47,xyy 9.9
508 achondroplasia 9.8
509 atrial standstill 1 9.8
510 burkitt lymphoma 9.8
511 cryoglobulinemia, familial mixed 9.8
512 hashimoto thyroiditis 9.8
513 immunoglobulin switch sequences 9.8
514 inclusion body myositis 9.8
515 kaposi sarcoma 9.8
516 systemic lupus erythematosus 9.8
517 mastocytosis, cutaneous 9.8
518 osteoporosis 9.8
519 nephrolithiasis, calcium oxalate 9.8
520 paroxysmal extreme pain disorder 9.8
521 pneumothorax, primary spontaneous 9.8
522 sister chromatid exchange, frequency of 9.8
523 small cell cancer of the lung 9.8
524 smith-magenis syndrome 9.8
525 thrombocytopenic purpura, autoimmune 9.8
526 thrombophilia due to thrombin defect 9.8
527 triiodothyronine receptor auxiliary protein 9.8
528 down syndrome 9.8
529 vitiligo-associated multiple autoimmune disease susceptibility 6 9.8
530 ataxia-telangiectasia 9.8
531 celiac disease 1 9.8
532 epidermodysplasia verruciformis 1 9.8
533 bernard-soulier syndrome 9.8
534 leprosy 3 9.8
535 microcephaly 1, primary, autosomal recessive 9.8
536 mycosis fungoides 9.8
537 ocular motor apraxia 9.8
538 reticulum cell sarcoma 9.8
539 schinzel-giedion midface retraction syndrome 9.8
540 glanzmann thrombasthenia 9.8
541 graves disease 1 9.8
542 werner syndrome 9.8
543 xeroderma pigmentosum, complementation group d 9.8
544 xeroderma pigmentosum, variant type 9.8
545 body mass index quantitative trait locus 11 9.8
546 wiskott-aldrich syndrome 9.8
547 hemophilia b 9.8
548 ataxia and polyneuropathy, adult-onset 9.8
549 kearns-sayre syndrome 9.8
550 retinitis pigmentosa 11 9.8
551 budd-chiari syndrome 9.8
552 body mass index quantitative trait locus 9 9.8
553 body mass index quantitative trait locus 8 9.8
554 meningioma, radiation-induced 9.8
555 vitiligo-associated multiple autoimmune disease susceptibility 1 9.8
556 bone mineral density quantitative trait locus 3 9.8
557 meningioma, familial 9.8
558 body mass index quantitative trait locus 4 9.8
559 body mass index quantitative trait locus 10 9.8
560 hypereosinophilic syndrome, idiopathic 9.8
561 anxiety 9.8
562 body mass index quantitative trait locus 7 9.8
563 myocardial infarction 9.8
564 severe cutaneous adverse reaction 9.8
565 rhabdoid tumor predisposition syndrome 1 9.8
566 bone mineral density quantitative trait locus 8 9.8
567 thrombocytopenia 4 9.8
568 colorectal cancer 3 9.8
569 body mass index quantitative trait locus 12 9.8
570 body mass index quantitative trait locus 14 9.8
571 bone mineral density quantitative trait locus 15 9.8
572 cyanosis, transient neonatal 9.8
573 beta-thalassemia 9.8
574 nail disorder, nonsyndromic congenital, 10 9.8
575 body mass index quantitative trait locus 18 9.8
576 pachyonychia congenita 3 9.8
577 thrombocytopenia 6 9.8
578 hydrops, lactic acidosis, and sideroblastic anemia 9.8
579 body mass index quantitative trait locus 19 9.8
580 diarrhea 9 9.8
581 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
582 body mass index quantitative trait locus 20 9.8
583 bacterial sepsis 9.8
584 autoimmune glomerulonephritis 9.8
585 erythema multiforme 9.8
586 familial adenomatous polyposis 9.8
587 brugada syndrome 9.8
588 severe congenital neutropenia 9.8
589 vitamin b12 deficiency 9.8
590 secondary progressive multiple sclerosis 9.8
591 fibroma 9.8
592 ductal carcinoma in situ 9.8
593 ptosis 9.8
594 cardiac arrest 9.8
595 lymphoproliferative syndrome 9.8
596 salmonellosis 9.8
597 bone resorption disease 9.8
598 fibrous dysplasia 9.8
599 myeloid neoplasms associated with pdgfrb rearrangement 9.8
600 endocarditis 9.8
601 perforated corneal ulcer 9.8
602 tonsillitis 9.8
603 meningoencephalitis 9.8
604 osteomalacia 9.8
605 thrombotic thrombocytopenic purpura 9.8
606 primary polycythemia 9.8
607 hypospadias 9.8
608 lipoid nephrosis 9.8
609 hydronephrosis 9.8
610 arteriovenous malformation 9.8
611 tetanus 9.8
612 spinal meningioma 9.8
613 choroiditis 9.8
614 hypertensive retinopathy 9.8
615 cauda equina syndrome 9.8
616 patau syndrome 9.8
617 panuveitis 9.8
618 lymphocytic choriomeningitis 9.8
619 goiter 9.8
620 common variable immunodeficiency 9.8
621 primary biliary cirrhosis 9.8
622 graves' disease 9.8
623 secondary hyperparathyroidism 9.8
624 acute kidney tubular necrosis 9.8
625 hereditary spherocytosis 9.8
626 branch retinal artery occlusion 9.8
627 central retinal artery occlusion 9.8
628 megaloblastic anemia 9.8
629 pulmonary sarcoidosis 9.8
630 tuberous sclerosis 9.8
631 squamous cell papilloma 9.8
632 amenorrhea 9.8
633 rubeosis iridis 9.8
634 poems syndrome 9.8
635 toxic shock syndrome 9.8
636 papilledema 9.8
637 panniculitis 9.8
638 urticaria 9.8
639 angioedema 9.8
640 renovascular hypertension 9.8
641 lymphadenitis 9.8
642 keratosis 9.8
643 pneumothorax 9.8
644 neuroendocrine tumor 9.8
645 duodenal ulcer 9.8
646 cheilitis 9.8
647 thyroid gland cancer 9.8
648 cholecystitis 9.8
649 rectum cancer 9.8
650 rectum adenocarcinoma 9.8
651 ascending colon cancer 9.8
652 blood platelet disease 9.8
653 transient cerebral ischemia 9.8
654 arteriosclerosis 9.8
655 gangliocytoma 9.8
656 acromegaly 9.8
657 gastric antral vascular ectasia 9.8
658 splenic abscess 9.8
659 papilloma 9.8
660 synovitis 9.8
661 hemoglobinopathy 9.8
662 pulmonary tuberculosis 9.8
663 iga glomerulonephritis 9.8
664 testicular cancer 9.8
665 breast sarcoma 9.8
666 astrocytoma 9.8
667 gingival overgrowth 9.8
668 keratoacanthoma 9.8
669 teratoma 9.8
670 central nervous system disease 9.8
671 inappropriate adh syndrome 9.8
672 mammary paget's disease 9.8
673 cellulitis 9.8
674 mixed connective tissue disease 9.8
675 cavernous sinus thrombosis 9.8
676 choriocarcinoma 9.8
677 intermittent claudication 9.8
678 pulmonary fibrosis 9.8
679 arthropathy 9.8
680 thrombophlebitis 9.8
681 liver disease 9.8
682 erythrasma 9.8
683 juvenile xanthogranuloma 9.8
684 dysgerminoma 9.8
685 secretory meningioma 9.8
686 lymphoplasmacyte-rich meningioma 9.8
687 bilateral retinoblastoma 9.8
688 uremia 9.8
689 proliferative glomerulonephritis 9.8
690 ganglioneuroma 9.8
691 auricular cancer 9.8
692 demyelinating polyneuropathy 9.8
693 intestinal disease 9.8
694 pneumonia 9.8
695 acute t cell leukemia 9.8
696 congestive heart failure 9.8
697 paraplegia 9.8
698 reactive arthritis 9.8
699 follicular dendritic cell sarcoma 9.8
700 hypersplenism 9.8
701 adenoma 9.8
702 cerebrovascular disease 9.8
703 juvenile rheumatoid arthritis 9.8
704 hepatoblastoma 9.8
705 t-cell leukemia 9.8
706 monoclonal gammopathy of uncertain significance 9.8
707 adenomatoid tumor 9.8
708 situs inversus 9.8
709 retinal telangiectasia 9.8
710 end stage renal failure 9.8
711 chronic kidney disease 9.8
712 hemarthrosis 9.8
713 scabies 9.8
714 ileus 9.8
715 paralytic ileus 9.8
716 corneal ulcer 9.8
717 retinal artery occlusion 9.8
718 lung disease 9.8
719 nervous system disease 9.8
720 tongue cancer 9.8
721 in situ carcinoma 9.8
722 crohn's disease 9.8
723 lupus erythematosus 9.8
724 chorioretinitis 9.8
725 pemphigus 9.8
726 lichen planus 9.8
727 erythromelalgia 9.8
728 pulmonary embolism 9.8
729 encephalitis 9.8
730 neurofibroma 9.8
731 babesiosis 9.8
732 aphthous stomatitis 9.8
733 hemometra 9.8
734 acute leukemia of ambiguous lineage 9.8
735 acute monoblastic leukemia 9.8
736 anterior uveitis 9.8
737 candida glabrata 9.8
738 carcinoma showing thymus-like differentiation 9.8
739 chromosome 9q deletion 9.8
740 dextrocardia with situs inversus 9.8
741 drug reaction with eosinophilia and systemic symptoms 9.8
742 dwarfism 9.8
743 exfoliative dermatitis 9.8
744 familial episodic pain syndrome 9.8
745 graham-little-piccardi-lassueur syndrome 9.8
746 hansen's disease 9.8
747 lymphangiectasis 9.8
748 mosaic trisomy 9 9.8
749 oral cancer 9.8
750 plasma cell leukemia 9.8
751 primary biliary cholangitis 9.8
752 schinzel giedion syndrome 9.8
753 spinal shock 9.8
754 tetraploidy 9.8
755 tetrasomy 21 9.8
756 therapy related acute myeloid leukemia and myelodysplastic syndrome 9.8
757 triploidy 9.8
758 aneurysm 9.8
759 back pain 9.8
760 cytomegalovirus infection 9.8
761 dysphagia 9.8
762 encephalopathy 9.8
763 foot drop 9.8
764 posttransplant acute limbic encephalitis 9.8
765 cerebrofacial arteriovenous metameric syndrome 9.8
766 rapidly involuting congenital hemangioma 9.8
767 trisomy 1q 9.8
768 virus-associated trichodysplasia spinulosa 9.8
769 primary cutaneous anaplastic large cell lymphoma 9.8
770 alk-positive anaplastic large cell lymphoma 9.8
771 acute myeloid leukemia with t(6;9)(p23;q34) 9.8
772 secondary pulmonary alveolar proteinosis 9.8
773 erythema multiforme major 9.8
774 benign idiopathic neonatal seizures 9.8
775 argyria 9.8
776 premature aging 9.8
777 hypopigmentation of the skin 9.8
778 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.8
779 monosomy 22 9.8
780 thrombotic microangiopathy 9.8
781 refractory anemia 9.8
782 neuroblastoma 1 9.8
783 aplastic anemia 9.8
784 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.8
785 chronic eosinophilic leukemia 9.8
786 leukostasis 9.8
787 gout 9.8
788 candidiasis 9.8
789 colon adenocarcinoma 9.8
790 glomerulonephritis 9.8
791 acute kidney failure 9.8
792 cranial nerve palsy 9.8
793 childhood leukemia 9.8
794 chickenpox 9.8
795 priapism 9.8
796 hypereosinophilic syndrome 9.8
797 hypoglycemia 9.8
798 chromosomal triplication 9.8
799 hematopoietic stem cell transplantation 9.8
800 rare tumor 9.8
801 cafe-au-lait spots, multiple 9.8
802 gray platelet syndrome 9.8
803 nondisjunction 9.8
804 cyclic neutropenia 9.8
805 pernicious anemia 9.8
806 myeloperoxidase deficiency 9.8
807 sea-blue histiocyte disease 9.8
808 pleurisy 9.8
809 gastric ulcer 9.8
810 megacolon 9.8
811 dysentery 9.8
812 shigellosis 9.8
813 subleukemic leukemia 9.8
814 azoospermia 9.8
815 toxic megacolon 9.8
816 nocardiosis 9.8
817 anuria 9.8
818 subacute leukemia 9.8
819 histiocytosis 9.8
820 hypertrichosis 9.8
821 lymph node tuberculosis 9.8
822 aleukemic leukemia cutis 9.8
823 measles 9.8
824 acute respiratory distress syndrome 9.8
825 hemangioendothelioma 9.8
826 mycobacterium fortuitum 9.8
827 nodular regenerative hyperplasia 9.8

Comorbidity relations with Leukemia, Chronic Myeloid via Phenotypic Disease Network (PDN): (showing 3, show less)


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Leukemia, Chronic Myeloid:



Diseases related to Leukemia, Chronic Myeloid

Symptoms & Phenotypes for Leukemia, Chronic Myeloid

Human phenotypes related to Leukemia, Chronic Myeloid:

59 32 (showing 15, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myeloproliferative disorder 59 32 obligate (100%) Obligate (100%) HP:0005547
2 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
3 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
4 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
5 thrombocytopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001873
6 thrombocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0001894
7 leukocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0001974
8 poor appetite 59 32 frequent (33%) Frequent (79-30%) HP:0004396
9 abnormal basophil morphology 32 frequent (33%) HP:0001912
10 chronic myelogenous leukemia 32 HP:0005506
11 abnormality of blood and blood-forming tissues 59 Frequent (79-30%)
12 abnormality of granulocytes 59 Frequent (79-30%)
13 abnormality of basophils 59 Frequent (79-30%)
14 reduced leukocyte alkaline phosphatase 32 HP:0004852
15 ph-positive acute lymphoblastic leukemia 32 HP:0004848

Symptoms via clinical synopsis from OMIM:

57
Hematology:
chronic myelogenous leukemia
ph-positive acute lymphoblastic leukemia

Laboratory Abnormalities:
low leukocyte alkaline phosphatase activity
presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients
two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl)
detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease

Clinical features from OMIM:

608232

UMLS symptoms related to Leukemia, Chronic Myeloid:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Leukemia, Chronic Myeloid:

46 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.17 ABL1 BCR CRKL JAK2 KIT NRAS

Drugs & Therapeutics for Leukemia, Chronic Myeloid

Drugs for Leukemia, Chronic Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 465, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
3
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
6
Panobinostat Approved, Investigational Phase 2, Phase 3 404950-80-7 6918837
7
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
8
Morphine Approved, Investigational Phase 3 57-27-2 5288826
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
11 Orange Approved Phase 2, Phase 3
12
Mercaptopurine Approved Phase 3 50-44-2 667490
13
Acyclovir Approved Phase 3 59277-89-3 2022
14
Thioguanine Approved Phase 3 154-42-7 2723601
15
Pegaspargase Approved, Investigational Phase 3 130167-69-0
16
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
17
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
18
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
19
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
20
Ribavirin Approved Phase 3 36791-04-5 37542
21
Palivizumab Approved, Investigational Phase 3 188039-54-5
22
Dalteparin Approved Phase 3 9005-49-6
23
Captopril Approved Phase 3 62571-86-2 44093
24
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
25
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
26
Tazobactam Approved Phase 3 89786-04-9 123630
27
Piperacillin Approved Phase 3 66258-76-2 43672
28
Vancomycin Approved Phase 3 1404-90-6 441141 14969
29
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
30
Lorazepam Approved Phase 3 846-49-1 3958
31
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
32
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
33
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
34
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
35
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
36
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
37
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
38
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
39
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
40
Polyestradiol phosphate Approved Phase 3 28014-46-2
41
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
42
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
43 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
44 Anesthetics, Dissociative Phase 3
45 Dextrans Phase 2, Phase 3
46 Central Nervous System Depressants Phase 3
47 Tranquilizing Agents Phase 3
48 Anti-Anxiety Agents Phase 3
49 Serotonin Antagonists Phase 3
50 Antipruritics Phase 3
51 Antipsychotic Agents Phase 3
52 Respiratory System Agents Phase 3
53 Antiparasitic Agents Phase 3
54 Antiprotozoal Agents Phase 3
55 Iron-Dextran Complex Phase 3
56 14-alpha Demethylase Inhibitors Phase 3
57 Cytochrome P-450 CYP3A Inhibitors Phase 3
58 Cytochrome P-450 Enzyme Inhibitors Phase 3
59 Steroid Synthesis Inhibitors Phase 3
60 Anesthetics, Intravenous Phase 3
61 Adjuvants, Anesthesia Phase 3
62 Anesthetics Phase 3
63 Anesthetics, General Phase 3
64 HH-GV-678 Phase 3
65 Narcotics Phase 3
66 Analgesics, Opioid Phase 3
67 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
68 Antitussive Agents Phase 3
69 beta-Lactamase Inhibitors Phase 3
70 Excitatory Amino Acid Antagonists Phase 3
71 Excitatory Amino Acids Phase 3
72 valacyclovir Phase 3
73 Antihypertensive Agents Phase 3
74
Hydroxyitraconazole Phase 3
75 calcium heparin Phase 3
76 Heparin, Low-Molecular-Weight Phase 3
77 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
78 Cytochrome P-450 CYP2C19 Inhibitors Phase 3
79 Piperacillin, Tazobactam Drug Combination Phase 3
80 Liposomal amphotericin B Phase 3
81 Angiotensin-Converting Enzyme Inhibitors Phase 3
82 triamcinolone acetonide Phase 3
83 Triamcinolone hexacetonide Phase 3
84 Triamcinolone diacetate Phase 3
85 Interferon alpha-2 Phase 2, Phase 3
86 Interferon-alpha Phase 3
87 interferons Phase 3
88 Topoisomerase Inhibitors Phase 3
89 Antineoplastic Agents, Phytogenic Phase 3
90
Homoharringtonine Phase 3 285033
91 Adjuvants, Immunologic Phase 3
92 Gemtuzumab Phase 2, Phase 3
93 Contraceptives, Oral Phase 3
94 Contraceptives, Oral, Combined Phase 3
95 Contraceptive Agents Phase 3
96 Norgestimate, ethinyl estradiol drug combination Phase 3
97 Estradiol 3-benzoate Phase 3
98 Estradiol 17 beta-cypionate Phase 3
99
Hydroxychloroquine Approved Phase 2 118-42-3 3652